💊 Suvorexant/Lemborexant Orexin Receptor Blockade Simulator

Orexin-Driven Wakefulness

Orexin neurons keep the brain awake and alert.

• ~70,000: Orexin neurons (hypothalamus) (small, powerful population)
• OX1 & OX2: Receptor subtypes (Gq-coupled GPCRs)
• 4+: Wake centers targeted (LC, TMN, raphe, BF)
• 100%: Baseline wake signal (normal daytime tone)

Orexin neuron anatomy

Neurons cluster tightly within the lateral hypothalamus.

Receptor distribution

OX1 favors locus coeruleus; OX2 favors TMN, cortex.

Arousal maintenance

Continuous orexin firing sustains stable daytime wakefulness.

Orexin neuron loss causes narcolepsy — the opposite disorder.

Suvorexant & Lemborexant Dosing

A dual orexin receptor antagonist is swallowed before bed.

• ~12 h: Suvorexant half-life (oral tablet)
• ~17–19 h: Lemborexant half-life (oral tablet)
• 1–4 h: Time to peak plasma (Tmax range)
• 10–20 mg: Typical dose (patient-specific)

Absorption

Drug crosses the gut wall into the bloodstream.

Blood-brain barrier crossing

Lipophilic molecule reaches hypothalamic receptors quickly.

Dose-dependent exposure

Higher dose raises peak brain drug concentration.

Both drugs are DORAs — dual orexin receptor antagonists.

Competitive OX1/OX2 Receptor Blockade

Drug molecules outcompete orexin for the same binding pocket.

• Competitive: Binding mode (reversible antagonism)
• High: OX2 affinity (key sleep-relevant target)
• ~65–80%: Occupancy at standard dose (typical clinical range)
• Displaced: Orexin fate (blocked, not destroyed)

Competitive kinetics

Drug and orexin compete for the same receptor pocket.

Occupancy dynamics

Higher plasma levels push occupancy toward saturation.

Reversible mechanism

Blockade fades naturally as the drug clears.

DORAs block signaling without themselves activating the receptor.

Wake-Promoting Circuits Lose Drive

Downstream arousal centers quiet without orexin input.

• Reduced: Locus coeruleus firing (norepinephrine drops)
• Reduced: TMN histamine tone (histaminergic signal fades)
• Declining: Cortical arousal (EEG shifts toward sleep)
• Falling: Wake signal strength (tracks occupancy rise)

Downstream silencing

Norepinephrine and histamine output taper off.

Multi-hub effect

One blockade point dims several arousal hubs.

Gradual transition

Arousal fades smoothly, not abruptly.

This graded quieting differs from benzodiazepine-style global sedation.

Natural Sleep Onset

Lowered arousal signaling finally lets sleep occur.

• ~30–45 min: Median time to sleep onset (dose-dependent)
• None: GABA-A receptor involvement (distinct mechanism)
• Low: Dependence risk vs benzodiazepine (no reinforcing euphoria)
• Preserved: Sleep architecture (normal REM/NREM cycling)

Sleep architecture preserved

REM and NREM stages remain largely normal.

No GABA-A involvement

Mechanism avoids the benzodiazepine receptor pathway entirely.

Dependence profile

Lower abuse liability than classic hypnotics.

Orexin blockade sleep differs fundamentally from GABA-A sedation.